ERBB2 and breast carcinoma: The antitumoral activity of the vaccines was evaluated in BALB/c mice pretreated with candidate vaccines and control VLPs with or without adjuvants (AddaVax or Poly (I:C)) and then challenged with the HER-2-positive mammary carcinoma cell line TuBo.